Psychedelic biotech sector aggregate market cap will not recover to 2024 highs before 2026-09-30, absent an FDA approval or clear NDA acceptance for a psychedelic compound.

Psychedelic drug companies' stock prices fell sharply from their 2024 highs and haven't bounced back. Without an actual FDA approval or a clear sign that one is coming, investors see no reason to pour money back in. The sector needs real regulatory wins to recover.

All major tracked psychedelic biotech equities are trading significantly below 2024 highs with no near-term binary catalyst visible. MDMA NDA remains unresolved with supplemental data requests outstanding. Psilocybin is not at NDA stage. Institutional capital inflows are contingent on regulatory de-risking. Sector recoveries of this magnitude historically require a binary approval event; without one, mean-reversion to 2024 highs before Q4 2026 is implausible. Confidence trimmed slightly from 0.83: 'market cap recovery' is measurable but depends on index composition clarity.